Drugs / CD45 Mab
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00706316 Background | Dec 2007 → Aug 2009 | nasopharyngeal carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD45 Mab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00706316 ↗ |
| Modality | Monoclonal antibody | “Patients will also receive an antibody called CD45 Mab prior to CTL infusion in order to allow for better expansion of the infused CTLs in the patients.” NCT00706316 ↗ |
| Route | Intravenous | “One time infusion (IV) at one of the following dose levels:” NCT00706316 ↗ |